Caenorhabditis elegans as an Infection Model for Pathogenic Mold and Dimorphic Fungi: Applications and Challenges

Chukwuemeka Samson Ahamefule1,2,3, Blessing C. Ezeuduji4, James C. Ogbonna3, Anene N. Moneke3, Anthony C. Ike3, Cheng Jin1,2, Bin Wang1,5* and Wenxia Fang1,5*

1 National Engineering Research Center for Non-Food Biorefinery, Guangxi Academy of Sciences, Nanning, China, 2 College of Life Science and Technology, Guangxi University, Nanning, China, 3 Department of Microbiology, University of Nigeria, Nsukka, Nigeria, 4 Department of Microbiology, University of Jos, Jos, Nigeria, 5 State Key Laboratory of Non-Food Biomass and Enzyme Technology, Guangxi Academy of Sciences, Nanning, China

The threat burden from pathogenic fungi is universal and increasing with alarming high mortality and morbidity rates from invasive fungal infections. Understanding the virulence factors of these fungi, screening effective antifungal agents and exploring appropriate treatment approaches in in vivo modeling organisms are vital research projects for controlling mycoses. Caenorhabditis elegans has been proven to be a valuable tool in studies of most clinically relevant dimorphic fungi, helping to identify a number of virulence factors and immune-regulators and screen effective antifungal agents without cytotoxic effects. However, little has been achieved and reported with regard to pathogenic filamentous fungi (molds) in the nematode model. In this review, we have summarized the enormous breakthrough of applying a C. elegans infection model for dimorphic fungi studies and the very few reports for filamentous fungi. We have also identified and discussed the challenges in C. elegans-mold modeling applications as well as the possible approaches to conquer these challenges from our practical knowledge in C. elegans-Aspergillus fumigatus model.

Keywords: Caenorhabditis elegans, dimorphic fungi, filamentous fungi, in vivo model, pathogenicity, high-throughput screening

INTRODUCTION

Pathogenic fungi pose an enormous global threat to humanity, leading to millions of deaths and substantial financial losses annually (Fisher et al., 2012; Rhodes, 2019). Morbidity and mortality rates from opportunistic fungal pathogens, such as Candida albicans, Aspergillus fumigatus, and Cryptococcus neoformans, have been increasing for some years, especially in immunocompromised patients (Pal, 2017; Linder et al., 2019; de Sousa-Neto et al., 2020). Addressing the pathogenesis of these fungal pathogens and finding controllable strategies are crucial and urgent. To tackle this threat, model organisms are required to conduct research focusing on the identification of virulence factors, screening of effective antifungal agents, and exploring appropriate treatment approaches.
Several model organisms have been adopted for studying of dimorphic and filamentous pathogenic fungi, including invertebrate models such as *Drosophila melanogaster* (Lamaris et al., 2008; Regulin and Kempken, 2018; Sampao et al., 2018; Wurster et al., 2019), *Galleria mellonella* (Gomez-Lopez et al., 2014; Long et al., 2018; Silva et al., 2018; Staniszewska et al., 2020), *Bombyx mori* (Matsumoto et al., 2013; Uchida et al., 2016; Nakamura et al., 2017; Matsumoto and Sekimizu, 2019), *Caenorhabditis elegans* (Okoli and Bignell, 2015; Ahamefule et al., 2020a), and vertebrate models such as mice (Fakhim et al., 2018; Skalski et al., 2018; Wong et al., 2019; Ahamefule et al., 2020a), and *C. elegans* is a microscopic multicellular nematode that lives freely in soil (Muhammed et al., 2012; Kim et al., 2017). Advantages, such as short life cycle, physiological simplicity, transparent body, complete sequenced genome, mature genetic manipulation system, and no requirement for ethical license, have greatly encouraged the wide adoption of this nematode as a model organism in scientific research with assorted applications across several research fields (Okoli et al., 2009; Ballestriero et al., 2010; Huang et al., 2014; Jiang and Wang, 2018). Some of these applications have been established for decades now whereas others are still in their nascent stages undergoing several studies. Nematode infection by the natural nematophagous obligate filamentous fungus *Drechmeria coniospora* is a common incidence in nature. *C. elegans* is usually applied for studying the innate immunity of nematodes to this fungus (Engelmann et al., 2011; Couillault et al., 2012; Zugasti et al., 2016). This nematode model has also been explored as an *in vivo* model for studying infections of human pathogenic filamentous fungi (Okoli and Bignell, 2015; Ahamefule et al., 2020a).

Application of the nematode model for dimorphic pathogenic fungi studies has resulted in numerous publications whereas only a few publications thus far have been recorded for human dimorphic and nondimorphic fungi studies, such as *Talaromyces* (Penicillium) marneffei, an important clinical dimorphic fungus, *Candida albicans* species such as *C. tropicalis* (Brihlante et al., 2016; Feistel et al., 2019; Pedroso et al., 2019), *C. krusei* (De Aguilar Cordeiro et al., 2018; Kunyeit et al., 2019), and *C. auris* (Eldesouky et al., 2018a; Mohammad et al., 2019). Another important clinical dimorphic fungus, *Talaromyces* (Penicillium) marneffei, has also been studied in a *C. elegans* model for both virulence tests and antifungal agent efficacy evaluations (Huang et al., 2014; Sangkanu et al., 2021).

Virulence factors of *C. albicans* such as genes involved in hyphal filamentation and biofilm formation (Romanowski et al., 2012; Sun et al., 2015; Holt et al., 2017), intestinal adhesion and colonization (Rane et al., 2014a; Muthamil et al., 2018; Priya and Pandian, 2020), important virulence enzymes (Ortega-Riveros et al., 2017; Song et al., 2019), transcription factors (Jain et al., 2013; Hans et al., 2019a), and environmental and nutrient factors (Hammond et al., 2013; Lopes et al., 2018; Hans et al., 2019b; Wong et al., 2019) have been identified in a *C. elegans* model to strengthen our understanding of the *in vivo* pathogenesis of this important fungal pathogen (Table 1). The virulence traits of some other non-*albicans* species (both dimorphic and nondimorphic) have also been investigated with this nematode model (Table 1). Similarly, virulence factors such as pigmentation and hyphal filamentation have been demonstrated to be critical pathogenic features of *T. marneffei* in a *C. elegans* infection model (Huang et al., 2014; Sangkanu et al., 2021). *C. elegans* gfp-4; sek-1 worms have mostly been used in these studies (aside from the wild-type strain, N2) because of their inability to produce progeny at 25°C due to the gfp-4 mutation and their susceptibility to pathogens due to sek-1 mutation, thus making the worms immunocompromised for infection by opportunistic human fungi (Huang et al., 2014; Okoli and Bignell, 2015; Ahamefule et al., 2020a).

Moreover, the adoption of a *C. elegans* model for searching and screening of effective bioactive compounds against several species of *Candida* has also received much attention. Effective bioactive compounds from marine habitats (Subramenium et al., 2017; Ganesh Kumar et al., 2019), plant parts (Shu et al., 2016; Pedroso et al., 2019), and other sources (Table 2) have been discovered because of their *in vivo* efficacies against several *Candida* species and were simultaneously evaluated for their cytotoxicity in a *C. elegans* model. Compounds such as alizarin, chrysazin, sesquiterpene, and purpurin were discovered to be highly effective in *in vivo* assays with effective doses ranging from 1 to 10 µg/ml (Table 2), indicating potential future prospects for antifungal drug research and discovery. Other compounds such as thymol (Shu et al., 2016), coumarin (Xu et al., 2019), and theophylline (Singh et al., 2020), were only effective at high concentrations of 64, 2, and 1.6 mg/ml, respectively (Table 2). Most of these compounds were certified as nontoxic at such effective concentrations as they were able to rescue infected nematodes and significantly elongated their lifespan (Table 2).

### APPLICATION OF *C. elegans* FOR DIMORPHIC FUNGI STUDIES

*C. elegans* has been extensively used for studying several dimorphic fungi of clinical relevance. The most devastating and pathogenic dimorphic fungus that has been adequately explored with this nematode model is *Candida albicans* (Hans et al., 2019a; Hans et al., 2019b; Song et al., 2019; Venkata et al., 2020) and a few other non-*albicans* species such as *C. tropicalis* (Brihlante et al., 2016; Feistel et al., 2019; Pedroso et al., 2019), *C. krusei* (De Aguilar Cordeiro et al., 2018; Kunyeit et al., 2019), and *C. auris* (Eldesouky et al., 2018a; Mohammad et al., 2019). Another important clinical dimorphic fungus, *Talaromyces* (Penicillium) marneffei, has also been studied in a *C. elegans* model for both virulence tests and antifungal agent efficacy evaluations (Huang et al., 2014; Sangkanu et al., 2021).

### Table 1

| Virulence Factor | Description | Source |
|-----------------|-------------|--------|
| Pigmentation    | Necessity for infection | *C. elegans* gfp-4; sek-1 worms |
| Hyphal filamentation | Critical features | *C. elegans* gfp-4; sek-1 worms |

### Table 2

| Source | Compounds | Effectiveness |
|--------|-----------|--------------|
| Marine habitats | Alizarin | Effective |
| Plant parts | Chrysazin | Effective |
| Other sources | Coumarin | Effective |
|            | Theophylline | Effective |

*Table 2: Effective bioactive compounds against *Candida* species*
| Candida spp. | C. elegans strain used | Identified virulence factors/conditions | Effect on host | References |
|-------------|-----------------------|----------------------------------------|---------------|------------|
| C. albicans | N2 Bristol (wild type) and sek-1Δ worms | Transcription factor CAS5 Kinase CEX1 | Avirulence or attenuated virulence of pathogen in host. | Feistel et al. (2019) |
| C. albicans, C. dubliniensis, C. tropicalis, C. parapsilosis | N2 Bristol (wild type) and sek-1Δ worms | Screen diverse pathogen strain backgrounds and species | C. albicans, C. tropicalis, and C. dubliniensis gave the most virulent effect on healthy nematode populations while C. parapsilosis, C. tropicalis, and C. albicans were the most virulent on immunocompromised worms | Feistel et al. (2019) |
| C. albicans | glp-4; sek-1 adult worms | Alcohol dehydrogenase 1 (ADH1) | Significant (p < 0.05) increase in survival time of worms infected by ADH1 mutant strain (adh1Δ/Δ) compared with the wild-type and reconstituted strains | Song et al., 2019 |
| C. albicans | N2 L4-young adult worms | Filamentation and virulence induced by phosphate conditions | Strain ICU1 caused mortality in worms in a phosphate-dependent manner while ICU12 caused mortality both in low and high phosphate conditions albeit consistent with degree of filamentation. Worms generally displayed an avoidance behavior on C. albicans grown in low phosphate medium | Romanowski et al. (2012) |
| C. albicans | N2 L4 worms | Prevacuolar protein sorting gene (VPS4) needed for extracellular secretion of aspartyl proteases | Attenuated virulence by vps4Δ (66 h median survival) compared with wild type, DAY185 (42 h), and reintegrated strains (45 h) | Rane et al. (2014a) |
| C. albicans | N2 Bristol larval and adult worms | Effects of microgravity on virulence | Reduced virulence in both larval and adult worms in spaceflight; reduced virulence in only larval and not adult worms in clinorotation all compared with static ground controls | Hammond et al. (2013) |
| C. albicans | N2 Bristol L4 worms | Hypoxia (1% oxygen) | Enhanced significant virulence (p < 0.001) leading to more than 80% worm mortality compared with controls | Lopes et al. (2018) |
| C. albicans | AU37 (glp-4; sek-1) worms | Limiting phospholipid synthesis | Approximately 23%–38% virulence reduction in mutant strains (LRO1, CHO1, and LPT1) compared with control | Wong et al. (2019) |
| C. albicans | glp-4; sek-1 adult worms | Transcription coactivator SPT20 | Attenuated virulence. Absence of hyphae filamentation in worms infected by mutant strains as against visible hyphae protrusion recorded in approximately half of dead worms infected by both wild-type and reintegrated strains at 48 h | Tan et al. (2014) |
| C. albicans | N2 young adult worms | [helix-loop-helix/leucine zipper (bHLH/Zip) transcription factor CaRTG3 | Significant increased survival rate (p < 0.05) of worms infected with rtg3 mutant strain (43.3%) compared with the wild-type (6.6%) and revertant (10%) strains | Hans et al., 2019a |
| C. albicans + Staphylococcus epidermidis | glp-4; sek-1 L3 and L4 worms | Biofilm and hyphal filamentation | Significantly reduced survival rate (p < 0.05) of coinfected worms (47%) compared with single infection by C. albicans hyphae (63%) and yeasts (81.5%) phenotypes | Holt et al. (2017) |
| C. albicans | glp-4; sek-1 adult worms | Iron-sulfur subunit of succinate dehydrogenase SDH2 | More than 85% mortality of worms infected with wild-type and reintegrated strains (all with visible hyphae) compared with 0% mortality and total absence of hyphae in worms infected with mutant (sdh2Δ/Δ) at 120 h | Bi et al. (2018) |
| C. albicans | N2 L4 worms | Proton pump V-ATPase | The tetR-VMA2 mutant was avirulent | Rane et al. (2014b) |
| C. albicans | glp-4; sek-1 L4 worms | Molecular chaperone Hsp104 | Significant increase in survival rate (p < 0.05) in Hsp104 homozygous mutant strain (17.2%) relative to heterozygous mutant (12.9%), wild-type (6.0%) and reconstituted (9.3%) strains by Day 7 | Fiori et al. (2012) |
| C. albicans | N2 Bristol and CB767 [bli-3(e767)/I] worms from egg stage | Transcription factor Cap1 required for countering reactive oxygen species (ROS) stress | Cap1 is required for virulence of C. albicans in nematode model. Strains lacking CAP1 induced Dar phenotype less frequently with attenuated virulence compared with the wild-type strain. Worms that could not produce ROS due to a mutation in the host oxidase showed early signs of disease and succumbed to an infection with the cap1Δ/Δ null mutant | Jain et al. (2013) |
| C. albicans | N2 L4 worms | Magnesium deprivation | 20% worm survival after 8 days of treatment compared with 100% mortality in control without treatment | Hans et al., 2019b |

(Continued)
The drug resistance threat of *Candida* species, similar to most other pathogens, is constantly increasing, leading to increased incidences of mortality and morbidity (Sanguinetti et al., 2015; Popp et al., 2017; Popp et al., 2019; Prasad et al., 2019). *C. elegans* has also proven to be an effective *in vivo* model for studying the infection of several azole-resistant *C. albicans* (Chang et al., 2015; Sun et al., 2018) and *C. auris* (Eldesouky et al., 2018a; Eldesouky et al., 2018b) strains. Studies have demonstrated the *in vivo* efficacy of some bioactive compounds applied singly or in combination with initially resistant antifungal drugs in the treatment of infected nematodes (Table 3).

Compounds such as 2-(5,7-dibromoquinolin-8-yl)oxy)-N’-(4-nitrobenzylidene) acetylhydrazide (Elghazawy et al., 2017; Mohammad et al., 2018) and phenylthiazole small molecules (Mohammad et al., 2019) are among the recently demonstrated effective compounds with good outcomes in nematode candidiasis (with effective dose concentrations of ≥4 and ≥5 µg/mL, respectively) against fluZ-resistant *C. albicans* and/or *C. auris* (Table 3). The combination of caffeic acid phenethyl ester (CAPE) and fluZ (Sun et al., 2018) as well as the sulfamethoxazole and voriconazole (voZ) combination (Eldesouky et al., 2018a) effectively rescued *C. elegans* worms infected by azole-resistant *C. albicans* and *C. auris*, respectively (Table 3).

The search for alternative treatment drugs with new inhibition mechanisms against pathogenic fungi such as *C. albicans* is a pressing need. Obtaining effective compounds that may not necessarily have a direct effect on *Candida* planktonic cells but affect critical virulence factors has recently been made possible by evaluating the efficacy of the compounds in a *C. elegans* infection model (Graham et al., 2017; Subramenium et al., 2017; Manoharan et al., 2018) (Table 4).

Remarkably, some compounds such as loureirin A (Lin et al., 2019), camphor, and fenchyl alcohol (Manoharan et al., 2017b) are effective compounds protecting infected worms at concentration doses less than the *in vitro* MICs (Table 4). Cascarilla bark oil, α-longipinene, linalool (Manoharan et al., 2018), and *Enterococcus faecalis* bacteriocin (EntV) (Graham et al., 2017) were reported to be quite potent in rescuing infected worms at low effective concentration doses, such as ≥0.001% for cascarilla bark oil, α-longipinene and linalool and 0.1 nM for EntV (Table 4).

These compounds usually rescue infected nematodes through other pathways such as direct effects on cardinal virulence factors and/or by stimulating/enhancing the immune responses of the host against pathogens (Okoli et al., 2009; Peterson and Pukkila-Worley, 2018; Ahamemule et al., 2020b). Such compounds may only be screened and identified through *in vivo* assays since they usually show little or no antimicrobial activities in *in vitro* assays. The adoption of simple *in vivo* models such as *C. elegans* significantly supports the screening and identification of more such compounds, which may expand the narrative of the usual antifungal therapies that primarily address direct effects on causative pathogens.

The application of live biotherapeutic products (LBPs) consisting mainly of probiotics is another alternative approach for the treatment of nematode candidiasis. Such alternative
### TABLE 2 | Evaluation of antifungal bioactive compounds in the *C. elegans* model.

| *Candida* spp. | *C. elegans* host | Effective antifungal compound/agent | Effective concentrations (µg/ml) | Effect | Reference |
|----------------|-------------------|------------------------------------|-------------------------------|--------|-----------|
| *C. albicans*  | N2 Bristol CF512  | Alizarin, chrysazin, and purpurin   | >2                            | By Day 4, the survival rates of worms in the presence of 2 µg/ml alizarin, chrysazin, purpurin, and fluconazole (fluZ) control were >60%, >50%, >60%, and <50%, respectively. At 1 mg/ml, alizarin had no cytotoxic effect on nematodes whereas chrysazin, purpurin, and fluZ reduced worms survival by >60%, 35%, and >95%, respectively | Manoharan et al. (2017a) |
| *C. albicans*  | N2 young adults   | Magnolol and honokiol              | 16                            | Both compounds significantly (p < 0.0001) protected and increased the lifespan of infected worms compared with infected untreated worms by Day 5. The antifungal compounds also significantly (p < 0.01) reduced colonization of *C. albicans* in the nematodes | Sun et al. (2015) |
| *C. albicans*  | Adult worms       | Coumarin                           | 2.0 mg/ml                      | Coumarin at concentrations of 0. 5–2.0 mg/ml significantly (p < 0.05) protected infected worms from death. However, coumarin at 2 mg/ml was significantly (p < 0.05) toxic to worms | Xu et al. (2019) |
| *C. albicans*  | glp-4; sek-1 L4 worms | Gallic acid, hexyl gallate, octyl gallate, and dodecyl gallate | 1–60                          | Significant (p < 0.05) increased survival rates of worms (13%–33%, 18%–33%, 12%–31%, and 14%–46%) when treated with galic acid, hexyl gallate, octyl gallate, or dodecyl gallate, respectively. Dodecyl gallate was the most effective in protecting worms from *Candida* infection. However, higher concentrations of these compounds (60 and 120 µg/ml) were toxic to worms | Singulani et al. (2017) |
| *C. albicans*  | N2 worms          | Kalpanaxsaponin A (KPA)            | 8, 16                          | KPA protected and increased the survival time of worms (5–6 days) compared with the untreated control (4 days). KPA also showed no cytotoxicity on worms at 64 µg/ml for 2 days | Li et al. (2019) |
| *C. albicans*  | glp-4; sek-1 worms | Chiloscyphenol A (CA)              | 8, 16                          | CA significantly (p < 0.001) prolonged the survival of infected worms compared with 1% DMSO control. CA at 16 µg/ml prevented hyphae filamentation and maintained worms at their usual curly growth condition. However, CA of ≥32 µg/ml was toxic to worms | Zheng et al. (2018) |
| *C. albicans*  | glp-4; sek-1 young adult worms | 2,6-bis[E-(4-pyridyl)methylidene] cyclohexanone (PMC) | 8                             | PMC treatment significantly (p < 0.0015) increased the survival rate of infected worms, similar to fluZ treatment at 4 µg/ml | de Sà et al. (2018) |
| *C. albicans*  | AL37 (sek-1; glp-4) L4 worms | Ebselen                           | 4, 8                           | Ebselen treatment at 4 and 8 µg/ml significantly (p < 0.05) reduced *C. albicans* load in infected worms when compared with the untreated control groups, same as amphotericin B (AmB), fluZ, and flucytosine (fluc) treatments | Thangamani et al. (2017) |
| *C. albicans*  | N2 L4/adult worms | Vanillin (van)                    | 125                           | Van protected and enhanced the survival of infected worms compared with untreated control within 4 days. Van also had no cytotoxic effects on nematodes by Day 4 of treatment | Venkata et al. (2020) |
| *C. albicans*  | N2 young adults   | Floricolin C (FC)                 | 8, 16, 32                      | FC significantly (p < 0.001) enhanced the survival of infected worms at 16 µg/ml giving the highest survival rate compared with the untreated control by Day 6. FC at 64 µg/ml had only little cytotoxic effect on worms within 6 days | Zhang et al. (2018) |
| *C. albicans*  | N2 L4/adult worms | Geraniol (Ger)                    | 135                           | Ger enhanced the survival of infected nematodes compared to untreated control within 3 days of assay. Ger was also able to reduce persistence of *C. albicans* in worm guts. Furthermore, Ger at 135 µg/ml did not display cytotoxic effect on worms compared to control by Day 3 | Singh et al. (2018) |
| Candida spp. | C. elegans host | Effective antifungal compound/agent | Effective concentrations (µg/ml) | Effect | Reference |
|-------------|----------------|----------------------------------|----------------------------------|--------|-----------|
| C. glabrata, C. krusei, C. tropicalis, and C. orthopsilosis | AU37 late L4 worms | Cupressus sempervirens essential oil (EO), Citrus limon EO, gallic acid, and Litsea cubeba EO | Varied with pathogen and effective compounds | Among the C. glabrata-infected worms treated with C. sempervirens EO (15.62, 31.25, and 62.5 µg/ml), C. limon EO (125, 250, and 500 µg/ml) or gallic acid (15.62, 31.25, and 62.5 µg/ml) for 4 days, only treatment group with C. sempervirens EO sustained a higher survival rate of worms (>60%). C. krusei-infected worms treated with L. cubeba EO (31.25, 62.5, and 125 µg/ml) or gallic acid (62.5, 125, and 250 µg/ml) did not witness cure from candidiasis. C. limon EO treatment (125 and 500 µg/ml) of C. tropicalis-infected worms gave 40% and 10%–15% worm survival rate, respectively. While C. sempervirens EO treatment (15.62–62.5 µg/ml) of C. orthopsilosis-infected worms increased survival rate to 80%–85% Day 4 postinfection. C. sempervirens and L. cubeba EOs (31.25–125 µg/ml) as well as gallic acid (15.62–250 µg/ml) were not toxic to worms compared with untreated control. Additionally, C. limon EO at 125 µg/ml was not toxic to worms but became significant toxic at higher concentrations of 250 µg/ml (p < 0.05) and 500 µg/ml (p < 0.0001) compared with untreated control | Pedroso et al. (2019) |
| C. albicans | N2 L4/young adult worms | Monoterpenoid perillyl alcohol (PA) | 175 and 350 | PA enhanced and prolonged infected nematodes with survival rates of 80% and 75% at 175 and 350 µg/ml, respectively, compared with untreated control with 16% survival by Day 7 postinfection. The persistence of C. albicans in the intestines of worms was reduced by PA. PA was also not toxic to C. elegans at 350 µg/ml after 7 days of incubation | Ansari et al. (2018) |
| C. albicans | glp-4; sek-1 worms | Solasodine-3-O-β-D-glucopyranoside (SG) | ≥8 | SG significantly (p < 0.0001) protected and prolonged the lifespan of infected C. elegans compared with the 1% DMSO control, inhibiting the hyphal filamentation of C. albicans in infected worms by Day 6 of postinfection. Moreover, SG was not toxic to worms at 64 µg/ml in 2 days of incubation | Li et al. (2015) |
| C. albicans | N2 L4/young adult worms | Theophylline (THP) | 1,600 | THP gave over 50% more survival rate of infected worms than the untreated infected control after 6 days postinfection. THP was able to drastically lower the persistence of C. albicans in nematode gut. Additionally, THP did not show any toxicity at 1.6 mg/ml compared with untreated control for 6 days of treatment | Singh et al. (2020) |
| C. albicans | N2 and several mutant* worms | Thymol | 64 mg/ml | Thymol significantly (p < 0.01) increased the survival rate and mean lifespan (10.5 ± 0.4 days) of infected C. elegans compared with untreated infected worms (6.1 ± 0.5 days) within 10 days postinfection. Thymol elicited important immunomodulatory response of C. elegans against C. albicans thus significantly (p < 0.01) reduced fungal burden in treated infected worms compared with untreated control | Shu et al. (2016) |
| C. albicans | Young adult worms | Sesquiterpene compound | ≥10 | Sesquiterpene compound prolonged the lifespan of infected worms with >70% survival rate up to 20 µg/ml treatment but became toxic at higher concentration of 50 µg/ml compared with untreated control | Ganesh Kumar et al. (2019) |

*KU25/pmk-1(km25) IV, AU1/sek-1(ag1) X, FK171/mek-1(xs54) X, AU3/nsy-1(ag3) II, and DA1750/adEx1750[PMK-1::GFP+rol 6(su1006)].
| Candida spp. | C. elegans host | Kind of drug resistance and MIC | Antifungal compound/agent | Time of preinfection (min) | Effect | Reference |
|-------------|----------------|-------------------------------|---------------------------|---------------------------|--------|-----------|
| C. albicans | AU37 L4 worms   | fluZ                           | 2-(5,7-Dibromoquinolin-8-yloxy)-N’-(4-nitrobenzyldiene) acetohydrazide (4b) | 90 | Compound 4b exhibited broad-spectrum antifungal activity towards species of Candida, Cryptococcus, and Aspergillus at a concentration of 0.5 µg/ml, as well as enhanced survival of C. elegans infected with fluZ-resistant C. albicans. This compound targets metal ion homeostasis in nematode intestines compared with just CAPE, fluZ, or the untreated control (all at 2 µg/ml). | Elghazawy et al. (2017) and Mohammad et al. (2018) |
| C. albicans | N2 worms        | fluZ 256 µg/ml                 | Caffeic acid phenethyl ester (CAPE) and fluZ | 120 | CAPE plus fluZ synergistically increased the survival rate of infected worms significantly compared with single treatment with either CAPE or fluZ. CAPE plus fluZ also significantly (p < 0.01) reduced C. albicans burden in nematode intestines compared with just CAPE, fluZ, or the untreated control (all at 2 µg/ml). | Sun et al. (2018) |
| C. albicans | AU37 L4 worms   | fluZ >64 µg/ml                 | Phenylthiazole small molecule (compound 1) | 90 | Compound 1 (at 5 and 10 µg/ml) enhanced the survival of C. albicans-infected nematodes, giving >70% survival rate (just like 5 µg/ml of 5-fluorocytosine control) by Day 3 postinfection compared with 0% of untreated infected worms. Similarly, Compound 1 (at 10 µg/ml) prolonged C. auris-infected worms giving ~70% survival by Day 4 compared with 0% of untreated infected worms. | Mohammad et al. (2019) |
| C. albicans | glp-4; sek-1 worms | fluZ >128 µg/ml               | Pyridoxatin (PYR) | 120 | PYR rescued and prolonged infected nematodes in a dose-dependent manner with 4 µg/ml giving ~50% survival rate after 5 days of treatment. | Chang et al. (2015) |
| C. albicans | AU37 L4 worms   | fluZ >64 µg/ml; itZ >16 µg/ml | Sulfur drugsa + fluZ | 180 | Sulfur (10 × MICb) and fluZ (10 µg/ml) combinations gave a significant (p < 0.05) reduction of C. albicans burden in infected worms (which is comparable with 5-fluorocytosine control) after 24 h treatment compared with fluZ and the DMSO-untreated controls. There was no significant difference among the activities of the 4 sulfur with fluZ combinations. | Eldesouky et al. (2018b) |
| C. auris  | AU37 L4 worms   | Azole resistant; fluZ >128 µg/ml; voZ = 16 µg/ml; itZ = 2 µg/ml | Sulfamethoxazole + voZ | 30 | The combination of sulfamethoxazole (128 µg/ml) with voZ (0.5 µg/ml) prolonged the life of infected worms by ~70% as against only sulfamethoxazole, voZ, or untreated control which could not keep worms alive till Day 5. | Eldesouky et al. (2018a) |

**MIC**, minimum inhibition concentration. 
*a*Sulfamethoxazole (SMX), sulfadoxine (SDX), sulfadimethoxine (SDM), or sulfamethoxypyridazine (SMP). 
*b*MICs of SMX, SDX, and SMP = 512 µg/ml, while MIC of SDM = 1,024 µg/ml.
| **Table 4 | C. elegans model demonstrating alternative inhibition mechanisms against Candida species.** |
| **Candida spp.** | **C. elegans host** | **Effective antifungal agent** | **Effective concentrations (µg/ml)** | **Effect** | **Reference** |
| C. albicans | N2 Bristol CF512 | 7-Benzoxysterolide | 0.05 mM | 7-Benzoxysterolide gave nematode survival rate of >40% while the positive control (fluZ) gave >60% by Day 4, both showed significant (p < 0.05) increase of survival rates compared with the untreated control (8%). 7-Benzoxysterolide at 0.1 mM showed mild toxicity on worms with 22% survival rate compared with 55% survival by fluZ. 7-Benzoxysterolide protected infected worms by preventing hyphal filamentation through downregulation of important hyphae-specific and biofilm-related genes | Manoharan et al. (2018) |
| C. albicans | gfp-4; sef-1 adult worms | Enterococcus faecalis bacteriocin (EntV) | 0.1 mM | Synthetic EntV (sEntV68) completely abrogated the virulence of C. albicans in infected worms, giving them lifespan similar to control worms fed with nematode food E. coli OP50. sEntV68 had no effect on the viability of C. albicans but protected the nematode by preventing hyphal morphogenesis. Separate treatments with cascarilla bark oil, α-longipinene, and linalool resulted in a significant (p < 0.05) increase in survival rate (>90%) of infected nematodes just like fluZ treatment (all at 0.01%) compared with the negative control (<5%) by Day 4. These antifungal compounds only became toxic at >0.5% (v/v) to the worms. Cascarilla bark oil, α-longipinene, and linalool protected infected worms by preventing hyphal filamentation but no direct effect on C. albicans planktonic cells | Graham et al. (2017) |
| C. albicans | fer-15; fem-1 adult worms | Cascarilla bark oil, α-longipinene, and linalool | ≥0.001% | Lou A significantly (p < 0.05) protected infected nematodes compared with the DMSO control in 144 h. More so, Lou A did not display any cytotoxic activity against the worms at 180 µg/ml. At effective in vivo concentration of 40 µg/ml, Lou A did not inhibit the growth of C. albicans but suppressed virulence trait such as adhesion, colonization, and hyphal filamentation | Manoharan et al. (2017c) |
| C. albicans | N2 young adult worms | Louxrin A (Lou A) | 40 | Lou A significantly (p < 0.05) protected infected nematodes compared with the DMSO control in 144 h. Louxrin A did not display any cytotoxic activity against the worms at 180 µg/ml. At effective in vivo concentration of 40 µg/ml, Lou A did not inhibit the growth of C. albicans but suppressed virulence trait such as adhesion, colonization, and hyphal filamentation | Lin et al. (2019) |
| C. albicans, C. glabrata, and C. tropicalis | L4 worms | Piperine | ≥BIC (32) | Piperine treatment helped worms to combat infection in a dose-dependent manner leading to a significant (p < 0.05) reduction in C. albicans load. Piperine did not result in cytotoxicity at sub-BIC, BIC, and 2 x BIC in worms. Piperine in vivo efficacy was mainly through hindering C. albicans colonization in nematode intestine by downregulating some important hyphae-specific genes but not affecting the growth and metabolism of the pathogen | Priya and Pandian (2020) |
| C. albicans, C. glabrata, and C. tropicalis | fer-15; fem-1 adult worms | Quinic acid and undecanoic acid | BIC (100) | QA-UDA at BIC increased the survival rates of worms infected by C. albicans, C. glabrata, and C. tropicalis to 216, 384, and 348 h compared with 156, 180, and 252 h of untreated infected worms, respectively. QA-UDA reduced in vivo biofilm formation and colonization of yeast pathogens in worms. These compounds had no effect on worm survival and viability at concentrations of 0.05% and 0.1% in 4 days, but they became significantly toxic (p < 0.05) at 0.5%. Camphor and fenchyl alcohol at BIC (approximately 50 times the MIC) had effect on C. albicans biofilm and hyphal filamentation but not on the planktonic cells | Muthamil et al. (2018) |
| C. albicans | L4 worms | 5-Hydroxymethyl-2-furaldehyde (5HM2F) | MBIC (400) | Increased survival time of infected worms when treated with 5HM2F (120 h) compared with 96 h of control group. 5HM2F displayed no cytotoxic effect on worms by120 h. 5HM2F below 500 µg/ml does not have antifungal effect on C. albicans except on some virulence factors such as biofilm formation, morphological transition, and production of secreted hydrolases | Subramenium et al. (2017) |

*MBIC for C. albicans, C. glabrata, and C. tropicalis in combination with QA/UDA were 100/5, 100/10, and 200/20 µg/ml, respectively. BIC, biofilm inhibition concentration; MBIC, minimum biofilm inhibitory concentration.
therapy is an interesting and promising option since pathogenic fungi are currently developing resistance to the few clinically available antifungal drugs (Sanguinetti et al., 2015; Prasad et al., 2019). Several species of Lactobacillus such as L. rhamnosus (Poupet et al., 2019a; Poupet et al., 2019b) and L. paracasei (de Barros et al., 2018) as well as probiotic yeasts—Saccharomyces cerevisiae and Issatchenka occidentalis (Kunyeit et al., 2019)—have demonstrated efficient rescue of worms infected with a number of Candida species. These therapeutic microorganisms drastically reduced the burden of the pathogens in the C. elegans intestine approximately 2 to 4 h postinfection treatment (Table 5).

The efficacy of these LBPs in reducing and/or eliminating fungal burden implies the future potential of LBPs in addressing the fungal menace. The demonstrated significant increase ($p < 2 \times 10^{-16}$) in worm mean lifespan (Poupet et al., 2019a; Poupet et al., 2019b) is so high that it has not been reported in any potent bioactive compounds or even established antifungal drugs. The fact that most of these LBPs are already established probiotics is yet another important parameter that would advance future research beyond nematode models.

The in vivo efficacy of known antifungal drugs and a number of repurposed drugs have also been applied in the treatment of nematode candidiasis. Several azoles (Souza et al., 2018; Hernando-Ortiz et al., 2020), echinocandins (Souza et al., 2018), polyenes—particularly amphotericin B (Hernando-Ortiz et al., 2020), and β-lactam antibiotics (in combination with vancomycin) (De Aguiar Cordeiro et al., 2018) have been evaluated for their in vivo efficacy at varying effective concentrations in rescuing worms infected with Candida species (Table 6). Synthesizedazole drugs, such as 1-(4-cyclopropyl-1H-1,2,3-triazol-1-yl)-2-(2,4-difluorophenyl)-3-(1H-1,2,4-triazol-1-yl) propan-2-ol, have also been evaluated for both efficacy and cytotoxicity in a C. elegans model (Chen et al., 2017).

Given that decades of searching for new antifungal agents have not truly resulted in new antifungal drugs, drug repurposing is a less expensive and welcome research prospect. The C. elegans infection model for evaluating the efficacy of repurposed drugs on candidiasis has attracted attention (Eldesouky et al., 2020b; Singh et al., 2020) (Table 6) due to the advantages of saving extensive time, cumbersome labor, and enormous cost of searching and obtaining new antifungal drugs.

C. elegans and Pathogenic Molds

The deadly opportunistic mold pathogen, A. fumigatus, ranks as the number 1 aetiological agent for aspergilloses in immunocompromised patients (Snelders et al., 2009; Fang and Latgé, 2018; Geißel et al., 2018) with an almost 100% mortality rate in some groups of patients (Darling and Milder, 2018; Geißel et al., 2018; Linder et al., 2019). This pathogen had not been well studied in C. elegans until recently. Okoli and Bignell (2015) were the first to demonstrate the possibility of adopting C. elegans for A. fumigatus infection. They set up the nematode model to study the pathogenicity of the clinical strain A. fumigatus Af293 for 72 h postinfection after an initial preinfection of 12 h. We recently reported a breakthrough in overcoming some of the challenges usually encountered in the C. elegans-mold infection system, one of which is removing spores that were not ingested by worms through a hand-made filter with a membrane-attached-on-tube. We were able to develop a stable and consistent C. elegans model for evaluating the virulence of A. fumigatus mutant strains that had previously been studied in other established models, including mice and insects. We also successfully demonstrated the possibility of in vivo testing of antifungal agents on nematode aspergillosis using the established model (Ahamefule et al., 2020a).

The established C. elegans-A. fumigatus model clearly demonstrated the progression of aspergillosis infection in nematodes using the A. fumigatus fluorescence strain, Af293-dsRed, showing that hyphal filamentation could actually emanate from any part of the infected worms against the previously reported concept of mainly the tail region (Okoli and Bignell, 2015; Ahamefule et al., 2020a). Our worm model was able to identify important virulence factors of A. fumigatus such as α-(1,3)-glucan synthase, melanin pigmentation, iron transporter, Zn2Cys6-type transcription factor, and mitochondrial thiamine pyrophosphate transporter, as mutant strains without these components (triple agsΔ, pksPΔ, ΔmrsA, ΔleuB, and ΔptA, respectively), all of which gave significantly attenuated virulence compared with the A. fumigatus parent strain KU80Δ. These reduced virulence patterns obtained by our C. elegans model were similar to previously reported attenuated virulence patterns of these A. fumigatus mutants in both vertebrate and insect models. The nematode model was also demonstrated to be an easy in vivo system to evaluate antifungal drug efficacy thus presenting the model as a desired platform for screening antifungal agents against A. fumigatus in the future (Ahamefule et al., 2020a).

CHALLENGES OF C. elegans APPLICATIONS IN MODELING PATHOGENIC MOLD

One of the biggest challenges usually encountered in the applications of the C. elegans model for filamentous fungal infection is the difficulty in infecting the worms through conidia. Worms usually avoid eating conidia unless they starve with no other option (Okoli and Bignell, 2015). This avoidance is unlike the case of dimorphic fungal and bacterial pathogens, where infection is never much of a problem as worms easily feed with no other option (Okoli and Bignell, 2015). This avoidance is unlike the case of dimorphic fungal and bacterial pathogens, where infection is never much of a problem as worms easily feed with no other option (Okoli and Bignell, 2015).

Giving the worms more time to starve and more access to the conidia (placed at four cardinal points) for ingestion is very important for establishing mold preinfection assays. Okoli and Bignell (2015) adopted a 12-h preinfection technique, while we modified to 16 h (Ahamefule et al., 2020a). The fact is that worms must be given such ample time to “force” them to ingest the mold conidia in a preinfection system since coinfection approach...
Ahamefule et al.  

**Caenorhabditis elegans**  

| Candida sp. | C. elegans host | LBP | Time of predilection/concentration (h) | Effective concentration (x/µl) | Reference |
|------------|-----------------|-----|--------------------------------------|-------------------------------|-----------|
| C. albicans | L4 young adult worms | Lactobacillus reuteri Lc035 | 2 | 2 and 4 h | Poupet et al. (2018a) |
| C. albicans | L3 and L4 worms | Lactobacillus paracasei Lcr35® | 2 | 2 and 4 h | Poupet et al. (2018b) |
| C. albicans | L3 and L4 worms | Saccharomyces cerevisiae (strain KTP) | 2 | 2 and 4 h | Kunyiet et al. (2019) |
| C. tropicalis | L3 and L4 worms | Lactobacillus paracasei Lcr35® | 2 | 48 | Poupet et al. (2019a) |
| C. tropicalis | L3 and L4 worms | Lactobacillus paracasei Lcr35® | 2 | 48 | Poupet et al. (2019b) |
| C. parapsilosis | L3 and L4 worms | Lactobacillus paracasei Lcr35® | 2 | 48 | Poupet et al. (2019c) |
| C. krusei | L3 and L4 worms | Lactobacillus paracasei Lcr35® | 2 | 48 | Poupet et al. (2019d) |
| C. glabrata | L3 and L4 worms | Lactobacillus paracasei Lcr35® | 2 | 48 | Poupet et al. (2019e) |
| C. occidentalis | L3 and L4 worms | Lactobacillus paracasei Lcr35® | 2 | 48 | Poupet et al. (2019f) |

**Application of live biotherapeutic products (LBP) to nematode candidiasis.**  

- **Candida albicans**  
  - C. elegans host: L4 young adult worms  
  - LBP: Lactobacillus reuteri Lc035  
  - Time of predilection/concentration (h): 2 and 4 h  
  - Effective concentration (x/µl): 2.0 x 10^6 cells/20 µl  
  - Reference: Poupet et al. (2018a)

- **Candida tropicalis**  
  - C. elegans host: L3 and L4 worms  
  - LBP: Lactobacillus paracasei Lcr35®  
  - Time of predilection/concentration (h): 2 and 4 h  
  - Effective concentration (x/µl): 48  
  - Reference: Poupet et al. (2019a)

- **Candida parapsilosis**  
  - C. elegans host: L3 and L4 worms  
  - LBP: Lactobacillus paracasei Lcr35®  
  - Time of predilection/concentration (h): 2 and 4 h  
  - Effective concentration (x/µl): 48  
  - Reference: Poupet et al. (2019c)

- **Candida krusei**  
  - C. elegans host: L3 and L4 worms  
  - LBP: Lactobacillus paracasei Lcr35®  
  - Time of predilection/concentration (h): 2 and 4 h  
  - Effective concentration (x/µl): 48  
  - Reference: Poupet et al. (2019d)

- **Candida glabrata**  
  - C. elegans host: L3 and L4 worms  
  - LBP: Lactobacillus paracasei Lcr35®  
  - Time of predilection/concentration (h): 2 and 4 h  
  - Effective concentration (x/µl): 48  
  - Reference: Poupet et al. (2019e)

- **Candida occidentalis**  
  - C. elegans host: L3 and L4 worms  
  - LBP: Lactobacillus paracasei Lcr35®  
  - Time of predilection/concentration (h): 2 and 4 h  
  - Effective concentration (x/µl): 48  
  - Reference: Poupet et al. (2019f)

**TABLE 5**  

The tremendous health hazards of pathogenic fungi cannot be overemphasized. Better understanding of *in vivo* pathogeneses and identification of virulence factors are urgent and imperative to fight against these fungi. Screening, identifying and repurposing effective compounds/drugs against them as well as obtaining and optimizing effective treatment alternatives are desirable at this time. Therefore, developing, optimizing and applying better modelling organisms such as *C. elegans* is (which is usually adopted for most dimorphic fungi modeling) cannot work well for mold pathogens (Okoli et al., 2009; Okoli and Bignell, 2015; Ahamefule et al., 2020a). As conidia germinate very fast even before the worms have ingested enough spores in killing assay medium, a relatively less nutritious medium was adopted for pre-infection assay to avoid the quick growth and flooding of hyphal filaments in the rich killing assay medium (brain heart infusion medium); otherwise later experimental procedures will be severely limited (Okoli and Bignell, 2015; Ahamefule et al., 2020a).

Another challenging aspect in setting up the *C. elegans*-mold model is the separation of noningested conidia from worms after pre-infection stage. Failure at this stage leads to the germination of unseparated spores in killing or antifungal screening media thus obstructing experimental progress. Although our designed membrane-attached-on-tube filter (with a 35-µm pore diameter) was able to remove a great deal of noningested conidia, the separation was not 100% efficient. Modifying the membrane pore size to an appropriate diameter should help improve the filtration efficiency by allowing faster and better removal of conidia while keeping the preinfected L4/young adult worms (Figure 1). Even though the separation efficiency of noningested spores becomes 100% or close to it, hyphae growth in killing medium would still not be completely eliminated, particularly if the experiment is scheduled to go beyond 72 h postinfection. This is because we have discovered that some conidia could be egested out of the nematode intestine into the killing medium and still retain their viability of germinating to hyphae, which is a big challenge to tackle and severely affect the experiment.

Hyphal filamentation usually occurs in infected worms. Unlike most studied dimorphic fungi whose external hyphal protrude when worms were already dead (and could therefore be easily transferred), numerous worms infected with filamentous fungi such as *A. fumigatus* (Ahamefule et al., 2020a), *A. flavus*, and some strains of *Penicillium* (that we have studied in our laboratory), were discovered to still be alive with protruded hyphae. This makes these worms stuck to the killing assay plates and therefore difficult to remove (Ahamefule et al., 2020a). Such filamentation usually becomes profuse, growing and spreading very fast and may eventually obstruct visibility and affect the experimental results. Regulating the number of immunocompromised worms in killing assays, especially for highly virulent pathogenic molds, is an option to ameliorate this menace (Figure 1).

**CONCLUSIONS**

The tremendous health hazards of pathogenic fungi cannot be overemphasized. Better understanding of *in vivo* pathogeneses and identification of virulence factors are urgent and imperative to fight against these fungi. Screening, identifying and repurposing effective compounds/drugs against them as well as obtaining and optimizing effective treatment alternatives are desirable at this time. Therefore, developing, optimizing and applying better modelling organisms such as *C. elegans* is
### TABLE 6 | *in vivo* activities of known and repurposed drugs against candidiasis in *C. elegans* models.

| *C. elegans* sp. | *C. elegans* host | Antifungal compounds | Effective concentrations (µg/ml) | Effect | Reference |
|-----------------|------------------|----------------------|---------------------------------|--------|-----------|
| *C. glabrata*, *C. nivariensis*, and *C. bracarensis* | *C. glabrata*, *C. nivariensis*, and *C. bracarensis* | Micafugin (MCF), CAS, and fluZ | Varying | MCF (4 µg/ml), CAS (4 µg/ml), AmB (1 µg/ml), and voZ (2 µg/ml) rescued infected worms with *C. glabrata* ATCC 90030 with survival rates of 90.6, 89.6, 82.4, 82.1, and 81.5%, respectively, by 120 h; higher similar rescues—96.8%, 94.6%, 91.8%, 85.2%, 83.8%, and 83.7%—were achieved for infected worms with *C. glabrata* | Hernando-Ortiz et al. (2020) |
| *C. parapsilosis* (sensu stricto), *C. rhizophilosis*, and *C. etapsilosis* | *C. glabrata*, *C. nivariensis*, and *C. bracarensis* | fluZ and CAS | ≥0.5 × MIC (fluZ MIC = 1.0; CAS MIC = 0.5) | Worm survival rates were dependent on the drug doses. Significant (*p* < 0.001) increase in survival of infected worms when treated with fluZ (≥57%) and CAS (69% and 74%) at 1 × MIC and 2 × MIC, respectively | Souza et al. (2018) |
| *C. albicans*, *C. parapsilosis*, *C. krusei*, and *C. tropicalis* | *C. glabrata*, *C. nivariensis*, and *C. bracarensis* | Cefepime (cef), imipenem (imi), meropenem (mer), amoxicillin (amo), and vancomycin (van) | PP and 2 × PP | Aro treatment significantly (*p* < 0.05) increased the virulence of *C. krusei* and *C. tropicalis* on the nematodes (in separate infections) at PP and 2 × PP. However, the virulence of *C. albicans*, *C. krusei*, *C. parapsilosis*, and *C. tropicalis* were not altered by the other tested antibiotics | De Aguiar Cordeiro et al. (2018) |
| *C. albicans* | *C. glabrata*, *C. nivariensis*, and *C. bracarensis* | 1-(4-Cyclopropyl-1H-1,2,3-triazol-1-yl)-2-(2,4-difluorophenyl)-3-(1H-1,2,4-triazol-1-yl)propan-2-ol (7l) | 16 | 7l significantly (*p* <0.05) prolonged and sustained infected worms, giving 70% survival rate compared with 60% recorded with 32 µg/ml of fluZ control | Chen et al. (2017) |
| *C. albicans* | *C. albicans* N2 L4/young adult worms | Theophylline (THP)* | 1,600 | THP gave over 50% more survival rate than the untreated infected control after 6 days postinfection. THP was able to drastically lower the persistence of pathogen in nematode gut. Additionally, THP did not show any toxicity at 1.6 mg/ml compared with untreated control by Day 6 | Singh et al. (2020) |
| *C. albicans*, *C. glabrata*, and *C. auris* | *C. albicans*, *C. glabrata*, and *C. auris* | Pitavastatin (Pit)* plus fluZ | Varying* | Pit plus fluZ displayed broad spectrum activity with varying outcomes depending on fluZ concentrations, and significantly reduced *C. albicans*, *C. glabrata*, and *C. auris* burden by ~82%–96%, ~84%–93% and 14%–92% compared with 233 ± 21, 344 ± 19, and 250 ± 25 CFU/ml of untreated controls, respectively | Eldesouky et al. (2020b) |

MIC, minimum inhibition concentration; PP, peak plasma concentration; *Repurposed drug.* *Pit = 0.5 × MIC; fluZ = 2, 8, and 32 µg/ml.
meaningful not only for dimorphic fungi but also for mold pathogens. Our review of the breakthrough applications of *C. elegans* for dimorphic fungi studies and progress/modifications of the *C. elegans*-mold infection model will provide a reference for studying fungal infections and developing antifungal agents.

**AUTHOR CONTRIBUTIONS**

CA and BE wrote the initial manuscript. JO, AM, AI, BW, CJ, and WF revised the manuscript. WF supervised the manuscript. All authors have read and agreed to the published version of the manuscript.

**FUNDING**

This work was supported by National Natural Science Foundation of China (31960032, 32071279), Guangxi Natural Science Foundation (2020GXNSFDA238008) to WF, Research Start-up Funding of Guangxi Academy of Sciences (2017YJ026) to BW, and Bagui Scholar Program Fund (2016A24) of Guangxi Zhuang Autonomous Region to CJ.

**REFERENCES**

Ahamefule, C. S., Ezedujji, B. C., Ogbonna, J. C., Moneke, A. N., Ike, A. C., Wang, B., et al. (2020b). Marine Bioactive Compounds Against *Aspergillus Fumigatus*: Challenges and Future Prospects. *Antibiotics* 9 (11), 813. doi: 10.3390/antibiotics9110813

Ahamefule, C. S., Qin, Q., Odiba, A. S., Li, S., Moneke, A. N., Ogbonna, J. C., et al. (2020a). *Caenorhabditis Elegans*-Based *Aspergillus Fumigatus* Infection Model for Evaluating Pathogenicity and Drug Efficacy. *Front. Cell. Infection Microbiol.* 10, 320. doi: 10.3389/fcimb.2020.00320

Ansari, M. A., Fatima, Z., Ahmad, K., and Hameed, S. (2018). Monoterpenoid Perillyl Alcohol Impairs Metabolic Flexibility of Candida Albicans by Inhibiting Glyoxylate Cycle. *Biochem. Biophys. Res. Commun.* 495 (1), 560–566. doi: 10.1016/j.bbrc.2017.11.064

Ballestriero, F., Thomas, T., Burke, C., Egan, S., and Kjelleberg, S. (2010). Identification of Compounds With Bioactivity Against the Nematode *Caenorhabditis Elegans* by a Screen Based on the Functional Genomics of the Marine Bacterium *Pseudoalteromonas Tunicate* D2. *Appl. Environ. Microbiol.* 76 (17), 5710–5717. doi: 10.1128/AEM.00695-10

Bi, S., Lv, Q. Z., Wang, T. T., Fuchs, B. B., Hu, D.-D., Anastassopoulou, C. G., et al. (2018). SDH2 Is Involved in Proper Hypha Formation and Virulence in *Candida Albicans*. *Future Microbiol.* 13 (10), 1141–1156. doi: 10.2217/fmb-2018-0033

Breger, J., Fuchs, B. B., Aperis, G., Moy, T. I., Asbel, F. M., and Mylonakis, E. (2007). Antifungal Chemical Compounds Identified Using a C. Elegans Pathogenicity Assay. *PloS Pathog.* 3 (2), e18. doi: 10.1371/journal.ppat.0030018

Brillante, R. S. N., Oliveira, J. S., Evangelista, A. J. J., Serpa, R., Silva, A. L. D., Aguar, F. R. M., et al. (2016). *Candida Tropicalis* From Veterinary and Human Sources Shows Similar *In Vitro* Hemolytic Activity, Antifungal Biofilm Susceptibility and Pathogenesis Against *Caenorhabditis Elegans*. *Veterinary Microbiol.* 30 (192), 213–219. doi: 10.1016/j.jvetmic.2016.07.022

Chang, W., Zhang, M., Li, Y., Li, X., Gao, Y., Xie, Z., et al. (2015). Lichen Endophyte Derived Pyridoxatin Inactivates Candida Growth by Interfering With Ergosterol Biosynthesis. *Biochim. Biophys. Acta* 1850 (9), 1762–1771. doi: 10.1016/j.bbabio.2015.05.005

Chen, H.-J., Jiang, Y.-J., Zhang, Y.-Q., Jing, Q.-W., Liu, N., and Wang, Y. (2017). New Triazole Derivatives Containing Substituted 1,2,3-Triazole Side Chains:
Design, Synthesis and Antifungal Activity. Chin. Chem. Lett. 28, 913–918. doi: 10.1016/j.ccl.2016.11.027
Chen, Y. Z., Yang, Y. L., Chua, W. L., You, M. S., and Lo, H. J. (2015). Zebrafish Egg Infection Model for Studying Candida Albicans Adhesion Factors. PloS One 10 (11), e0143048. doi: 10.1371/journal.pone.0143048
Couillaud, C., Fourquet, P., Pophillat, M., and Ewbank, J. (2012). A UPR-Independent Infection-Specific Role for a BIP/GRP78 Protein in the Control of Antimicrobial Peptide Expression in C. Elegans Ephiditis. Virulence 3 (3), 299–308. doi: 10.4161/viru.20384
Darling, B. A., and Milder, E. A. (2018). Invasive Aspergillosis. Pediatr. Rev. 39 (3), 476–478. doi: 10.1542/pir.2017-0129
De Aguiar Cordeiro, R., de Jesus Evangelista, A. J., Serpa, R., Colares de Andrade, A. R., Leite Mendes, P. B., Silva Franco, J. D., et al. (2011). A Comprehensive Analysis of Gene Expression Changes Provoked by Bacterial and Fungal Infection in C. Elegans. Viruses 3 (11), 4875–4911. doi: 10.3390/v3114875
Enghardt, S., Fatima, Z., and Hameed, S. (2019a). Magnesium Deprivation Affects Cellular Circuitry Involved in Drug Resistance and Virulence in Candida Albicans. J. Global Antimicrobial Resistance 17, 263–275. doi: 10.1016/j.jgar.2019.04.012
Farina, D. J., Elmostafa, R., Nguyen, N., Penley, M., Hickman, M. A., Fakhim, H., Vaezi, A., Dannaoui, E., Chowdhary, A., Nasiry, D., Faeli, L., et al. (2017). Preparation and Nanoformulation of New Quinolone Scaffold-Based Antimicrobial Peptide Expression in C. Elegans Epidermis. Chin. Chem. Lett. 808. doi: 10.1016/j.ccl.2017.05.008
Fisher, M. C., Henk, D. A., Briggs, C. J., Brownstein, J. S., Madoff, L. C., McCraw, S. L., et al. (2012). Emerging Fungal Threats to Animal, Plant and Ecosystem Health. Nature 484 (7393), 154–159. doi: 10.1038/nature10894
Ganesh Kumar, A., Balamurugan, K., Vijaya Raghuvan, R., Dhari, G., and Kirubagaran, R. (2019). Studies on the Antifungal and Serotonin Receptor Agonist Activities of the Secondary Metabolites From Piezotolerant Deep-Sea Fungus Fuscoschizotricha Sp. Mycologia 100 (2), 92–108. doi: 10.1080/21501203.2018.1541934
Garvey, E. P., Hoekstra, W. J., Moore, W. R., Schotzinger, R. J., Long, L., and Ghannoun, M. A. (2015). VT-1161 Dosed Once Daily or Once Weekly Exhibits Potent Efficacy in Treatment of Dermatophytosis in a Guinea Pig Model. Antimicrobial Agents Chemotherapy 59 (4), 1992–1997. doi: 10.1128/AAC.04902-14
Geibel, B., Lokko, V., Klugherr, I., Zhu, Z., Wagener, N., Kurzai, O., et al. (2018). Azole-Induced Cell Wall Carbohydrate Patches Kill Aspergillus Fumigatus. Nat. Commun. 9 (1), 3098. doi: 10.1038/s41467-018-05497-7
Gomez-Lopez, A., Forastiero, A., Cendejas-Bueno, E., Gregson, L., Mellado, E., Howard, S. J., et al. (2014). An Invertible Model to Evaluate Virulence in Aspergillus Fumigatus: The Role of Azole Resistance. Med. Mycology 52 (3), 311–319. doi: 10.1093/mmy/mty022
Grant, C. M., Cruz, M. R., Garbin, D. A., and Lorenz, M. C. (2017). Enterococcus Faecalis Bactericin EnfV Inhibits Hyphal Morphogenesis, Biofilm Formation, and Virulence of Candida Albicans. Proc. Natl. Acad. Sci. United States America 114 (45), 11407–11412. doi: 10.1073/pnas.1620431114
Hammond, T. G., Stodieck, L., Birdsell, H. H., Becker, J. L., Koenig, P., Hammond, J. S., et al. (2013). Effects of Microgravity on the Virulence of Listeria Monocytogenes, Enterococcus Faecalis, Candida Albicans, and Methicillin-Resistant Staphylococcus Aureus. Astrobiology 13 (11), 1081–1090. doi: 10.1089/ast.2013.09866
Hans, S., Fatima, Z., and Hameed, S. (2019a). Microbe Processing in the C. Elegans Nematode of Staphylococcus Epidermidis and Pathogens ABC Superfamily Transporter, Ergosterol and Chitin Levels Along With Biofilm Formation in Candida Albicans. J. Mycology Medicale 29 (3), 210–218. doi: 10.1016/j.jymycmed.2019.07.003
Hernando-Ortiz, A., Mateo, E., Ortega-Riveros, M., De-la-Pinta, I., Quindo, G., and Eraso, E. (2020). Caenorhabditis elegans as a Model System to Assess Candida glabrata, Candida nivariensis, and Candida braacarenis Virulence and Antifungal Efficacy. Antimicrob. Agents Chemother. 64 (10), e00824-20. doi: 10.1128/AAC.00824-20
Holt, J. E., Houston, A., Adams, C., Edwards, S., and Kjelleraas, B. V. (2017). Bifidobacterium Anaerolacticum Polymeric Substances in Polymicrobial Biofilm Infections of Staphylococcus Epidermidis and Candida Albicans Modelled in the Nematode Caenorhabditis Elegans. Pathog. Dis. 75 (5), e01052. doi: 10.1093/femsdp/fot052
Huang, X., Li, D., Xi, L., and Mylonakis, E. (2014). Caenorhabditis Elegans: A Simple Nematode Infection Model for Penicillium Marneffei. PloS One 9 (9), e108764. doi: 10.1371/journal.pone.0108764
Jain, C., Pastor, K., Gonzalez, A. Y., Lorenz, G., and Rao, R. P. (2013). The Role of Candida Albicans AP-1 Protein Against Host Derived ROS in In Vivo Models of Infection. Virulence 4 (1), 67–76. doi: 10.4161/viru.22700
Jiang, H., and Wang, D. (2018). The Microbial Zoo in the C. Elegans Intestine: Bacteria, Fungi and Viruses. Viruses 10 (2), 85. doi: 10.3390/v10020085
Johnson, C. H., Ayyadevara, S., McEwen, J. E., and Shmookler Reis, R. J. (2009). Design, Synthesis and Antifungal Activity. Chin. Chem. Lett. 20, 913–918. doi: 10.1016/j.ccl.2009.11.027
Kim, W., Hendricks, G. L., Lee, K., and Mylonakis, E. (2017). An Update on the Use of C. elegans for Preclinical Drug Discovery: Screening and Identifying Anti-Infective Drugs. Expert Opin. Drug Discov. 12 (6), 625–633. doi: 10.1080/17460441.2017.1319358
Kirenko, N. V., Kirenko, D. R., Larkins-Ford, J., Wahlby, C., Ruvkun, G., and Ausubel, F. M. (2013). Pseudomonas Aeruginosa Disrupts Caenorhabditis Elegans Iron Homeostasis, Causing a Hypoxic Response and Death. Cell Host Microbe 13 (4), 406–416. doi: 10.1016/j.chom.2013.03.003
this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Ahamefule, Ezeuduiji, Ogbonna, Monoke, Ike, Jin, Wang and Fang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.